Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics
Eric Karran, Bart De Strooper
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 4, pp. 306-318
Open Access | Times Cited: 485

Showing 1-25 of 485 citing articles:

Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics
Jeffrey L. Cummings
Drugs (2023) Vol. 83, Iss. 7, pp. 569-576
Open Access | Times Cited: 139
Mouse Models of Alzheimer’s Disease
Miyabishara Yokoyama, Honoka Kobayashi, Lisa Tatsumi, et al.
Frontiers in Molecular Neuroscience (2022) Vol. 15
Open Access | Times Cited: 133
Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics
Harald Hampel, Aya Elhage, Min Cho, et al.
Brain (2023) Vol. 146, Iss. 11, pp. 4414-4424
Open Access | Times Cited: 129
Recent advances in Alzheimer’s disease: Mechanisms, clinical trials and new drug development strategies
Jifa Zhang, Yinglu Zhang, Jiaxing Wang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 129
Alzheimer's disease: From immunotherapy to immunoprevention
Mathias Jucker, Lary C. Walker
Cell (2023) Vol. 186, Iss. 20, pp. 4260-4270
Open Access | Times Cited: 125
Microbiota from Alzheimer’s patients induce deficits in cognition and hippocampal neurogenesis
Stefanie Grabrucker, Moira Marizzoni, Edina Silajdžić, et al.
Brain (2023) Vol. 146, Iss. 12, pp. 4916-4934
Open Access | Times Cited: 113
The amyloid cascade hypothesis: an updated critical review
Kasper P. Kepp, Nikolaos K. Robakis, Poul Flemming Høilund‐Carlsen, et al.
Brain (2023) Vol. 146, Iss. 10, pp. 3969-3990
Open Access | Times Cited: 111
If amyloid drives Alzheimer disease, why have anti-amyloid therapies not yet slowed cognitive decline?
Christian Haass, Dennis J. Selkoe
PLoS Biology (2022) Vol. 20, Iss. 7, pp. e3001694-e3001694
Open Access | Times Cited: 105
Astrocyte calcium dysfunction causes early network hyperactivity in Alzheimer’s disease
Disha Shah, Willy Gsell, Jérôme Wahis, et al.
Cell Reports (2022) Vol. 40, Iss. 8, pp. 111280-111280
Open Access | Times Cited: 83
Exercise suppresses neuroinflammation for alleviating Alzheimer’s disease
Minghui Wang, Hu Zhang, Jiling Liang, et al.
Journal of Neuroinflammation (2023) Vol. 20, Iss. 1
Open Access | Times Cited: 83
Adult hippocampal neurogenesis in Alzheimer’s disease: A roadmap to clinical relevance
Evgenia Salta, Orly Lazarov, Carlos P. Fitzsimons, et al.
Cell stem cell (2023) Vol. 30, Iss. 2, pp. 120-136
Open Access | Times Cited: 78
Accelerating Alzheimer’s therapeutic development: The past and future of clinical trials
Adam L. Boxer, Reisa A. Sperling
Cell (2023) Vol. 186, Iss. 22, pp. 4757-4772
Open Access | Times Cited: 75
Neurovascular coupling mechanisms in health and neurovascular uncoupling in Alzheimer’s disease
Winston M Zhu, Ain Neuhaus, Daniel J. Beard, et al.
Brain (2022) Vol. 145, Iss. 7, pp. 2276-2292
Open Access | Times Cited: 70
An anti-amyloid therapy works for Alzheimer’s disease: why has it taken so long and what is next?
John Hardy, Catherine J. Mummery
Brain (2023) Vol. 146, Iss. 4, pp. 1240-1242
Open Access | Times Cited: 43
Pathological BBB Crossing Melanin-Like Nanoparticles as Metal-Ion Chelators and Neuroinflammation Regulators against Alzheimer’s Disease
Qianqian Huang, Chaoqing Jiang, Xue Xia, et al.
Research (2023) Vol. 6
Open Access | Times Cited: 42
Misfolded protein oligomers: mechanisms of formation, cytotoxic effects, and pharmacological approaches against protein misfolding diseases
Dillon J. Rinauro, Fabrizio Chiti, Michele Vendruscolo, et al.
Molecular Neurodegeneration (2024) Vol. 19, Iss. 1
Open Access | Times Cited: 42
Protein-based bioactive coatings: from nanoarchitectonics to applications
Chengyu Fu, Zhengge Wang, Xingyu Zhou, et al.
Chemical Society Reviews (2024) Vol. 53, Iss. 3, pp. 1514-1551
Closed Access | Times Cited: 24
Inflammatory aspects of Alzheimer’s disease
Pablo Botella Lucena, Michael T. Heneka
Acta Neuropathologica (2024) Vol. 148, Iss. 1
Closed Access | Times Cited: 23
Lessons Learned from Approval of Aducanumab for Alzheimer's Disease
Judith L. Heidebrink, Henry L. Paulson
Annual Review of Medicine (2024) Vol. 75, Iss. 1, pp. 99-111
Open Access | Times Cited: 22
Lipid Peroxidation Drives Liquid–Liquid Phase Separation and Disrupts Raft Protein Partitioning in Biological Membranes
Muthuraj Balakrishnan, Anne K. Kenworthy
Journal of the American Chemical Society (2024) Vol. 146, Iss. 2, pp. 1374-1387
Open Access | Times Cited: 21
Familial Alzheimer mutations stabilize synaptotoxic γ-secretase-substrate complexes
Sujan Devkota, Rui Zhou, Vaishnavi Divya Nagarajan, et al.
Cell Reports (2024) Vol. 43, Iss. 2, pp. 113761-113761
Open Access | Times Cited: 17
The advent of Alzheimer treatments will change the trajectory of human aging
Dennis J. Selkoe
Nature Aging (2024) Vol. 4, Iss. 4, pp. 453-463
Closed Access | Times Cited: 16
Proteomic analysis of Alzheimer’s disease cerebrospinal fluid reveals alterations associated with APOE ε4 and atomoxetine treatment
Eric B. Dammer, Anantharaman Shantaraman, Lingyan Ping, et al.
Science Translational Medicine (2024) Vol. 16, Iss. 753
Open Access | Times Cited: 16
Anti-herpetic tau preserves neurons via the cGAS-STING-TBK1 pathway in Alzheimer’s disease
Vanesa R. Hyde, Chaoming Zhou, J R Muñóz y Fernández, et al.
Cell Reports (2025), pp. 115109-115109
Open Access | Times Cited: 7
Second-generation anti-amyloid monoclonal antibodies for Alzheimer’s disease: current landscape and future perspectives
Byeong‐Hyeon Kim, Sujin Kim, Yunkwon Nam, et al.
Translational Neurodegeneration (2025) Vol. 14, Iss. 1
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top